Neuren Pharmaceuticals Set for Record A$70-77M Royalties as DAYBUE Sales Soar

Neuren Pharmaceuticals (ASX: NEU) is positioned for record royalty income in 2026 following partner Acadia Pharmaceuticals’ latest DAYBUE sales guidance. Acadia projects DAYBUE net sales of US$460-490 million for 2026, translating to expected royalty income of A$70-77 million for Neuren. The guidance builds on strong 2025 performance, with full-year DAYBUE sales reaching US$391 million (up 12% year-on-year) and delivering A$65 million in royalties to Neuren (up 15% year-on-year).

The Neuren DAYBUE Sales 2026 Guidance represents sustained commercial momentum entering the third full year since the Rett syndrome treatment launched in April 2023. Q4 2025 marked the strongest quarter to date, with net sales of US$110 million (up 13% versus prior corresponding period and 8% quarter-on-quarter) generating A$20 million in royalty income for Neuren (up 7% versus prior corresponding period and 21% quarter-on-quarter).

Q4 2025 delivers record patient numbers and quarterly sales

Q4 2025 established new benchmarks across multiple metrics since DAYBUE’s April 2023 launch. The number of unique patients receiving DAYBUE shipments reached a record 1,070 in Q4, continuing an upward trajectory from 1,006 patients in Q3 2025 and 987 in Q2 2025.

Community prescribing momentum has strengthened significantly, with 76% of new prescriptions now originating from community physicians outside specialist centres of excellence. This shift indicates DAYBUE has moved beyond early adopters among specialist Rett syndrome clinics into broader treatment protocols across mainstream paediatric neurology and developmental medicine practices.

The sequential patient growth and quarterly sales acceleration suggest DAYBUE has achieved sustainable commercial traction. Accelerating patient uptake combined with expanding community prescriber adoption indicates the treatment has progressed from specialist-driven early adoption into mainstream clinical practice.

Understanding royalty economics for pharmaceutical investors

Royalty income represents a capital-efficient mechanism for biotechnology companies to monetise drug development partnerships. Neuren receives tiered royalty payments based on DAYBUE net sales, without incurring manufacturing costs, sales force expenses, or ongoing commercial infrastructure requirements.

The royalty structure creates operating leverage as sales climb through successive tiers. For North America sales, Neuren receives 10% of net sales up to US$250 million annually, 12% on sales between US$250 million and US$500 million, 14% on sales between US$500 million and US$750 million, and 15% on sales exceeding US$750 million.

Outside North America, Neuren is entitled to royalty rates in the mid-teens to low-20s percentage range of net sales, providing higher margins on international commercial expansion.

Beyond recurring royalties, the partnership structure includes milestone payments triggered by regulatory and commercial achievements:

Milestones Already Received:

• US$100 million upfront payment (2018)
• US$10 million upon NDA acceptance for FDA review (2022)
• US$40 million upon first US commercial sale (2023)
• US$50 million from one-third share of Priority Review Voucher sold by Acadia for US$150 million (2024)

Future Milestone Opportunities:

• US$35 million upon first commercial sale in Europe
• US$15 million upon first commercial sale in Japan
• Additional milestones tied to second indication approvals and annual sales thresholds

The royalty model enables Neuren to capture value from DAYBUE’s commercial success whilst deploying capital toward pipeline advancement, rather than funding commercialisation infrastructure. As DAYBUE sales progress through royalty tiers, Neuren’s effective royalty rate increases, creating margin expansion without additional capital deployment.

DAYBUE STIX powder launch could unlock new patient populations

The FDA approved DAYBUE STIX powder formulation in December 2025, providing an alternative administration route for patients and families who find the liquid formulation challenging. Acadia launched STIX on a limited basis in Q1 2026, with full commercial availability targeted for the beginning of Q2 2026.

The powder formulation addresses a specific commercial opportunity. Acadia has indicated the product could potentially facilitate treatment of a significant number of additional patients from families who declined to initiate therapy or discontinued the liquid formulation.

Jon Pilcher, CEO

“The sustained momentum of DAYBUE in the US, together with international named patient programs, is underpinning a strengthening financial position for Neuren. The growing royalty income enhances our ability to advance our pipeline and maximise long-term shareholder value.”

The STIX formulation represents potential patient recapture (those who discontinued) and new patient acquisition (those who previously declined), without requiring additional research and development investment from Neuren. Acadia’s 2026 guidance of US$460-490 million does not explicitly quantify STIX’s contribution, suggesting the forecasts may be conservative regarding formulation-driven uptake.

European and Japanese regulatory pathways progressing

International expansion remains on track despite European regulatory complexity. Following formal adoption of the Committee for Medicinal Products for Human Use (CHMP) opinion at the end of February 2026, Acadia plans to request re-examination. The CHMP opinion on re-examination is expected by the end of Q2 2026.

Critically, Acadia’s 2026 guidance of US$460-490 million comprises US sales and international named patient programmes only, with no inclusion of EU commercial sales. Any European marketing authorisation in 2026 would represent pure upside to current guidance, triggering the US$35 million European milestone payment and higher-margin international royalties.

In Japan, Acadia’s Phase 3 clinical trial of trofinetide is ongoing, with top-line results expected between Q4 2026 and Q1 2027. The results would facilitate a marketing application planned for 2027. Japanese approval would trigger a US$15 million milestone payment and access to royalties in the mid-teens to low-20s percentage range on Japanese net sales.

European and Japanese pathways offer significant upside optionality not reflected in current guidance, with higher royalty rates and substantial milestone payments upon successful regulatory outcomes.

Pipeline optionality funded by royalty cashflows

Neuren’s second drug candidate, NNZ-2591, is advancing through Phase 3 development for Phelan-McDermid syndrome, funded by growing DAYBUE royalty income. The compound demonstrated positive Phase 2 results across three rare neurodevelopmental conditions:

1. Phelan-McDermid syndrome (Orphan Drug designation US and EU, Fast Track, Rare Pediatric Disease)
2. Pitt Hopkins syndrome (Orphan Drug designation US and EU, Fast Track, Rare Pediatric Disease)
3. Angelman syndrome (Orphan Drug designation US and EU, Fast Track, Rare Pediatric Disease)

The Phase 3 trial, named “Koala,” is a randomised, double-blind, placebo-controlled study evaluating safety and efficacy of NNZ-2591 in children aged 3 to 12 years with Phelan-McDermid syndrome and a 52-week open-label extension study.

Neuren is also developing NNZ-2591 for hypoxic ischaemic encephalopathy (HIE), a serious condition caused by brain injury before or shortly after birth. The pipeline represents multiple development programmes in rare neurological disorders, funded by DAYBUE royalties rather than equity dilution.

What the 2026 outlook means for Neuren shareholders

The 2026 royalty projection of A$70-77 million implies 8-18% growth above 2025’s A$65 million, based on conservative assumptions including North America royalty rates only and AUD/USD exchange rates of 0.70-0.72. The guidance excludes potential European commercial sales, STIX formulation upside beyond base forecasts, and favourable foreign exchange movements.

Multiple near-term catalysts could drive valuation re-rating throughout 2026:

• Q2 2026: STIX powder formulation achieves full commercial availability
• End of Q2 2026: CHMP re-examination opinion on European marketing authorisation
• Q4 2026 to Q1 2027: Japan Phase 3 trial top-line results

Each catalyst represents potential upside to the base royalty guidance. European approval would trigger the US$35 million milestone and higher-margin international royalties. STIX uptake could expand the patient base beyond current forecasts. Japanese Phase 3 success would position Neuren for a 2027 marketing application and subsequent US$15 million milestone.

The investment case combines growing base royalties (providing income visibility), international expansion optionality (offering substantial upside), formulation-driven patient growth (incremental to guidance), and funded pipeline advancement (multiple development programmes without dilution). The 2026 outlook establishes a floor for recurring income whilst preserving meaningful upside optionality across regulatory, commercial, and pipeline value drivers.

Get Healthcare Biotech News Before the Market Moves

Join 20,000+ investors receiving FREE real-time ASX alerts within minutes of release, complete with expert analysis. Click the “Free Alerts” button at StockWire X to get breaking healthcare and biotech announcements delivered straight to your inbox the moment they hit the market.